164 related articles for article (PubMed ID: 35054486)
1. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Shi L; Leung MH; Man EPS; So ZQ; Chan WL; Khoo US
Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054486
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer.
Tsoi H; Lok J; Man EP; Cheng CN; Leung MH; You CP; Chan SY; Chan WL; Khoo US
J Pathol; 2023 Oct; 261(2):156-168. PubMed ID: 37555303
[TBL] [Abstract][Full Text] [Related]
3. SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Fung NN; Man EPS; Leung MH; You CP; Chan WL; Chan SY; Khoo US
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190199
[TBL] [Abstract][Full Text] [Related]
4. Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer.
Tsoi H; Man EPS; Chau KM; Khoo US
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806019
[TBL] [Abstract][Full Text] [Related]
5. A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2.
Leung MH; Tsoi H; Gong C; Man EP; Zona S; Yao S; Lam EW; Khoo US
Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32110852
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Tsang WC; Man EPS; Leung MH; You CP; Chan SY; Chan WL; Khoo US
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293165
[TBL] [Abstract][Full Text] [Related]
7. BQ323636.1, a Novel Splice Variant to
Gong C; Man EPS; Tsoi H; Lee TKW; Lee P; Ma ST; Wong LS; Luk MY; Rakha EA; Green AR; Ellis IO; Lam EW; Cheung KL; Khoo US
Clin Cancer Res; 2018 Aug; 24(15):3681-3691. PubMed ID: 29420220
[No Abstract] [Full Text] [Related]
8. SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity.
Zhang L; Gong C; Lau SL; Yang N; Wong OG; Cheung AN; Tsang JW; Chan KY; Khoo US
Cancer Res; 2013 Jan; 73(1):246-55. PubMed ID: 23117886
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.
De Amicis F; Thirugnansampanthan J; Cui Y; Selever J; Beyer A; Parra I; Weigel NL; Herynk MH; Tsimelzon A; Lewis MT; Chamness GC; Hilsenbeck SG; Andò S; Fuqua SA
Breast Cancer Res Treat; 2010 May; 121(1):1-11. PubMed ID: 19533338
[TBL] [Abstract][Full Text] [Related]
11. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
[TBL] [Abstract][Full Text] [Related]
12. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
13. KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer.
Tsoi H; Man EP; Leung MH; Mok KC; Chau KM; Wong LS; Chan WL; Chan SY; Luk MY; Cheng CN; Khoo US
Clin Transl Med; 2021 Oct; 11(10):e554. PubMed ID: 34709749
[No Abstract] [Full Text] [Related]
14. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
15. Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer.
Tsoi H; You CP; Leung MH; Man EPS; Khoo US
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267559
[TBL] [Abstract][Full Text] [Related]
16. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
17. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
[TBL] [Abstract][Full Text] [Related]
18. MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells.
Kim S; Jeon M; Lee JE; Nam SJ
Oncol Rep; 2016 Apr; 35(4):2398-404. PubMed ID: 26780941
[TBL] [Abstract][Full Text] [Related]
19. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
D'Amato NC; Gordon MA; Babbs B; Spoelstra NS; Carson Butterfield KT; Torkko KC; Phan VT; Barton VN; Rogers TJ; Sartorius CA; Elias A; Gertz J; Jacobsen BM; Richer JK
Mol Cancer Res; 2016 Nov; 14(11):1054-1067. PubMed ID: 27565181
[TBL] [Abstract][Full Text] [Related]
20. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
